Free Trial
NASDAQ:LYEL

Lyell Immunopharma (LYEL) Stock Price, News & Analysis

Lyell Immunopharma logo
$11.20 -0.12 (-1.02%)
As of 11:46 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Lyell Immunopharma Stock (NASDAQ:LYEL)

Key Stats

Today's Range
$11.36
$12.00
50-Day Range
$7.99
$13.73
52-Week Range
$7.65
$32.40
Volume
6,018 shs
Average Volume
86,300 shs
Market Capitalization
$173.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00
Consensus Rating
Reduce

Company Overview

Lyell Immunopharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
67th Percentile Overall Score

LYEL MarketRank™: 

Lyell Immunopharma scored higher than 67% of companies evaluated by MarketBeat, and ranked 399th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Lyell Immunopharma has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no buy ratings, 1 hold rating, and 1 sell rating.

  • Amount of Analyst Coverage

    Lyell Immunopharma has only been the subject of 1 research reports in the past 90 days.

  • Read more about Lyell Immunopharma's stock forecast and price target.
  • Earnings Growth

    Earnings for Lyell Immunopharma are expected to grow in the coming year, from ($0.78) to ($0.70) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Lyell Immunopharma is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Lyell Immunopharma is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Lyell Immunopharma has a P/B Ratio of 0.43. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    3.59% of the float of Lyell Immunopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Lyell Immunopharma has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Lyell Immunopharma has recently decreased by 6.45%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Lyell Immunopharma does not currently pay a dividend.

  • Dividend Growth

    Lyell Immunopharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.59% of the float of Lyell Immunopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Lyell Immunopharma has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Lyell Immunopharma has recently decreased by 6.45%, indicating that investor sentiment is improving significantly.
    • Insider Buying vs. Insider Selling

      In the past three months, Lyell Immunopharma insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      22.30% of the stock of Lyell Immunopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

    • Percentage Held by Institutions

      66.05% of the stock of Lyell Immunopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

    • Read more about Lyell Immunopharma's insider trading history.
    Receive LYEL Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Lyell Immunopharma and its competitors with MarketBeat's FREE daily newsletter.

    LYEL Stock News Headlines

    Critical AI announcement set to ignite AI 2.0
    Markets are jittery. Rallies fade. Sectors rotate overnight. And the true impact of new tariffs and policy shifts hasn’t even hit the data yet. That’s why smart traders are turning to a strategy built for exactly this kind of market—fast, simple, and designed to react to real price action, not predictions.
    See More Headlines

    LYEL Stock Analysis - Frequently Asked Questions

    Lyell Immunopharma's stock was trading at $12.80 at the beginning of 2025. Since then, LYEL shares have decreased by 11.6% and is now trading at $11.32.

    Lyell Immunopharma, Inc. (NASDAQ:LYEL) posted its quarterly earnings results on Tuesday, May, 13th. The company reported ($3.60) EPS for the quarter, topping analysts' consensus estimates of ($3.80) by $0.20. The company earned $0.01 million during the quarter. Lyell Immunopharma had a negative net margin of 514,649.22% and a negative trailing twelve-month return on equity of 73.66%.

    Lyell Immunopharma's stock reverse split before market open on Friday, May 30th 2025.The 1-20 reverse split was announced on Friday, May 30th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 30th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

    Lyell Immunopharma (LYEL) raised $425 million in an initial public offering on Thursday, June 17th 2021. The company issued 25,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, BofA Securities, J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO.

    Lyell Immunopharma's top institutional investors include Alphabet Inc. (1.98%), TD Asset Management Inc (0.34%), Johnson & Johnson (0.28%) and Takeda Pharmaceutical Co. Ltd. (0.27%). Insiders that own company stock include Richard Klausner, Richard Klausner, Lynn Seely, Lynn Seely, Sumant Ramachandra, Charles W Newton, Charles W Newton, Otis W Brawley and Otis W Brawley.
    View institutional ownership trends
    .

    Shares of LYEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Based on aggregate information from My MarketBeat watchlists, some other companies that Lyell Immunopharma investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Broadcom (AVGO), Invesco QQQ (QQQ) and Palo Alto Networks (PANW).

    Company Calendar

    Last Earnings
    5/13/2025
    Today
    8/08/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Sector
    Medical
    Industry
    MED - DRUGS
    Sub-Industry
    Pharmaceutical Products
    Current Symbol
    NASDAQ:LYEL
    CIK
    1806952
    Fax
    N/A
    Employees
    270
    Year Founded
    N/A

    Price Target and Rating

    High Price Target
    $20.00
    Low Price Target
    $10.00
    Potential Upside/Downside
    +32.5%
    Consensus Rating
    Reduce
    Rating Score (0-4)
    1.50
    Research Coverage
    2 Analysts

    Profitability

    EPS (Trailing Twelve Months)
    ($25.00)
    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    -$342.99 million
    Net Margins
    -514,649.22%
    Pretax Margin
    -514,649.16%
    Return on Equity
    -73.66%
    Return on Assets
    -60.99%

    Debt

    Debt-to-Equity Ratio
    N/A
    Current Ratio
    7.49
    Quick Ratio
    7.49

    Sales & Book Value

    Annual Sales
    $65 thousand
    Price / Sales
    2,691.90
    Cash Flow
    N/A
    Price / Cash Flow
    N/A
    Book Value
    $26.21 per share
    Price / Book
    0.43

    Miscellaneous

    Outstanding Shares
    15,457,000
    Free Float
    12,010,000
    Market Cap
    $174.97 million
    Optionable
    Optionable
    Beta
    -0.19
    7 Stocks to Buy And Hold Forever Cover

    Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

    Get This Free Report

    This page (NASDAQ:LYEL) was last updated on 8/8/2025 by MarketBeat.com Staff
    From Our Partners